USPTO serial 77672421
MONDORARE
Reviewed by CopyMark Law Group
Reg. 4007941Status 710
- Filing date
- Status date
- Registration date
- Aug 9, 2011
- Examiner
- NELSON, EDWARD
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with MONDORARE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
James A. Long
JAMES A. LONG JIANQ CHYUN INTELLECTUAL PROPERTY OFFICE7TH FL.-1, NO. 100 ROOSEVELT RD. SEC. 2TAIPEI, 100TAIWANGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment or prophylaxis of infectious diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of immunological diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of autoimmune diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of cardiovascular diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of inflammatory diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of neurodegenerative diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of neurological diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of psychiatric diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of otorhinolaryngologic diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of eye diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of dental diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of kidney diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of liver diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of gastrointestinal diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of metabolic diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of gynecological diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of andrological diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of urologic diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of geriatric diseases and states in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of orthopaedic diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of diseases of the bones and joints in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of muscular diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of skin diseases in humans or animals; pharmaceutical preparations for the treatment or prophylaxis of pain in humans or animals; pharmaceutical preparations for the treatment of and preparation to surgical states in humans or animals; pharmaceutical preparations for anaesthesia in humans or animals; pharmaceutical preparations for obstetrics or abortion in humans or animals; pharmaceutical preparations for cosmetic purposes in humans or animals; Pharmaceutical preparations for treating respiratory diseases and asthma; Pharmaceutical preparations for treatment of pulmonary diseases; Pharmaceutical preparations for the treatment of hypertension; Pharmaceutical preparations for use in the treatment of cancer; Pharmaceutical preparations for use in chemotherapy; Biological preparations for medical purposes; Biological preparations for veterinary purposes; Bronchodilating preparations; Veterinary preparations for the treatment of infectious diseases; Veterinary preparations for the treatment of non-infectious diseases; pharmaceutical preparations, namely, contrast agents for radiography, x-ray radiography, computer tomography, magnetic resonance imaging, magnetic resonance tomography, ultrasonography or positron emission tomography; Chemical preparations for medical purposes; Chemical preparations for pharmaceutical purposes; Chemical reagents for medical or veterinary purposes; Chemico-pharmaceutical preparations for the treatment or prophylaxis of infectious diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of immunological diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of autoimmune diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of cardiovascular diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of inflammatory diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of neurodegenerative diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of neurological diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of psychiatric diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of otorhinolaryngologic diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of eye diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of dental diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of kidney diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of liver diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of gastrointestinal diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of metabolic diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of gynecological diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of andrological diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of urologic diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of geriatric diseases and states in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of orthopaedic diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of diseases of the bones and joints in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of muscular diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of skin diseases in humans or animals; Chemico-pharmaceutical preparations for the treatment or prophylaxis of pain in humans or animals; Chemico-pharmaceutical preparations for the treatment of and preparation to surgical states in humans or animals; Chemico-pharmaceutical preparations for anaesthesia in humans or animals; Chemico-pharmaceutical preparations for obstetrics or abortion in humans or animals; Chemico-pharmaceutical preparations for cosmetic purposes in humans or animals; Diagnostic preparations for clinical or medical use; Diagnostic preparations for veterinary use; Dietetic substances adapted for medical use; Disinfectants; Preparations for destroying vermin; Fungicides; Herbicides; Drugs for medical purposes; Medicines for the treatment or prophylaxis of dental diseases and states and dental cosmetic purposes; Medicines for the treatment or prophylaxis of infectious diseases in humans or animals; Medicines for the treatment or prophylaxis of immunological diseases in humans or animals; Medicines for the treatment or prophylaxis of autoimmune diseases in humans or animals; Medicines for the treatment or prophylaxis of cardiovascular diseases in humans or animals; Medicines for the treatment or prophylaxis of inflammatory diseases in humans or animals; Medicines for the treatment or prophylaxis of neurodegenerative diseases in humans or animals; Medicines for the treatment or prophylaxis of neurological diseases in humans or animals; Medicines for the treatment or prophylaxis of psychiatric diseases in humans or animals; Medicines for the treatment or prophylaxis of otorhinolaryngologic diseases in humans or animals; Medicines for the treatment or prophylaxis of eye diseases in humans or animals; Medicines for the treatment or prophylaxis of dental diseases in humans or animals; Medicines for the treatment or prophylaxis of kidney diseases in humans or animals; Medicines for the treatment or prophylaxis of liver diseases in humans or animals; Medicines for the treatment or prophylaxis of gastrointestinal diseases in humans or animals; Medicines for the treatment or prophylaxis of metabolic diseases in humans or animals; Medicines for the treatment or prophylaxis of gynecological diseases in humans or animals; Medicines for the treatment or prophylaxis of andrological diseases in humans or animals; Medicines for the treatment or prophylaxis of urologic diseases in humans or animals; Medicines for the treatment or prophylaxis of geriatric diseases and states in humans or animals; Medicines for the treatment or prophylaxis of orthopaedic diseases in humans or animals; Medicines for the treatment or prophylaxis of diseases of the bones and joints in humans or animals; Medicines for the treatment or prophylaxis of muscular diseases in humans or animals; Medicines for the treatment or prophylaxis of skin diseases in humans or animals; Medicines for the treatment or prophylaxis of pain in humans or animals; Medicines for the treatment of and preparation to surgical states in humans or animals; Medicines for anaesthesia in humans or animals; Medicines for obstetrics or abortion in humans or animals; Medicines for cosmetic purposes in humans or animals; Medical preparations for mouth care; Medical preparations for skin care; Sanitary preparations for medical use | SECTION 8 - CANCELLED | — |
| 035 | Business appraisals; Business consulting services for scientific projects in the field of medicine, pharmacy, biology, and chemistry or medicine-technology; Business information services for scientific projects in the field of medicine, pharmacy, biology, and chemistry or medicine-technology; Business inquiry services for scientific projects in the field of medicine, pharmacy, biology, and chemistry or medicine-technology; Business investigation services for scientific projects in the field of medicine, pharmacy, biology, and chemistry or medicine-technology; Business management and organization services for scientific projects in the field of medicine, pharmacy, biology, and chemistry or medicine-technology; Business management assistance services for scientific projects in the field of medicine, pharmacy, biology, and chemistry or medicine-technology; Business management consultancy services for scientific projects in the field of medicine, pharmacy, biology, and chemistry or medicine-technology; Business organization consultancy services for scientific projects in the field of medicine, pharmacy, biology, and chemistry or medicine-technology; Business acquisition and merger consultation in the field of medicine, pharmacy, biology, and chemistry or medicine-technology; Procurement of legal and technical know-how (franchising) in the field of medicine, pharmacy, pharmacology, biology, biotechnology, chemistry and medicine-technology; Procurement of scientific cooperations in the field of medicine, pharmacy, pharmacology, biology, biotechnology, chemistry and medicine-technology; Providing business consulting and management services for the commercialization of scientific projects in the field of medicine, pharmacy, biology, chemistry or medicine-technology | SECTION 8 - CANCELLED | — |
| 041 | Providing of training in the field of medicine, pharmacy, pharmacology, biology, biotechnology, chemistry and medicine-technology; Arranging and conducting of colloquiums in the field of medicine, pharmacy, pharmacology, biology, biotechnology, chemistry and medicine-technology; Arranging and conducting of conferences in the field of medicine, pharmacy, pharmacology, biology, biotechnology, chemistry and medicine-technology; Arranging and conducting of congresses in the field of medicine, pharmacy, pharmacology, biology, biotechnology, chemistry and medicine-technology; Arranging and conducting of seminars in the field of medicine, pharmacy, pharmacology, biology, biotechnology, chemistry and medicine-technology; Arranging and conducting of symposiums in the field of medicine, pharmacy, pharmacology, biology, biotechnology, chemistry and medicine-technology; Arranging and conducting of workshops training in the field of medicine, pharmacy, pharmacology, biology, biotechnology, chemistry and medicine-technology; Correspondence courses in the field of medicine, pharmacy, pharmacology, biology, biotechnology, chemistry and medicine-technology; Educational services, namely, providing courses of medicine, pharmacy, pharmacology, biology, biotechnology, chemistry and medicine-technology; Organization of exhibitions for cultural or educational purposes; Practical training demonstration in the field of medicine, pharmacy, pharmacology, biology, biotechnology, chemistry and medicine-technology | SECTION 8 - CANCELLED | — |
| 042 | Biological research; Chemical analysis; Chemical Research; Chemistry services, namely, performing commissioned preparations, syntheses, patent search and literature search in the field of chemistry; Cosmetic research; Technical research in the field of medicine, pharmacy, pharmacology, biology, biotechnology, chemistry or medicine-technology; Project studies Technical in the field of medicine, pharmacy, pharmacology, biology, biotechnology, chemistry or medicine-technology; Medical and scientific development and research services in the field of medical, biochemical, pharmaceutical and medicine-technological research; Commissioned research and development work in the field of medicine, pharmacy, pharmacology, biology, biotechnology, chemistry or medicine-technology; Commissioned development of pharmaceutical preparations; Medical and scientific research, namely, conducting and evaluating clinical trials of pharmaceutical preparations for statutory approval; Assessment of scientific projects, namely, evaluating their feasibility, scientific value and costs; Assessment of clinical studies and clinical trials; medical, bacteriological and biochemical laboratory services for diagnosis, analysis, research and drug development in the field of medicine | SECTION 8 - CANCELLED | — |
| 044 | Services of a hospital; Services of medical practitioner; Services of a medical clinic; Pharmacy advice in the field of medicine, pharmacy, pharmacology, biology, biotechnology, chemistry, medicine-technology, health policy, business administration or related legal affairs; Medical assistance services; Nursing services; Medical sample testing services for samples provided by patients, volunteers, persons compelled by law, persons compelled by military institutions, persons compelled by educational institutions or employers to provide body samples for diagnostic purposes, treatment purposes and fitness evaluation | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by mondoBIOTECH Laboratories AG
- Other trademarks owned by mondoBIOTECH Laboratories AG
- Other trademarks owned by mondoBIOTECH Laboratories AG
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named MONDORARE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 16, 2018 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Aug 9, 2011 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 24, 2011 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 24, 2011 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 21, 2011 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Apr 19, 2011 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 19, 2011 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 19, 2011 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 19, 2011 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 19, 2011 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 19, 2011 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Apr 15, 2011 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Apr 2, 2011 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Apr 1, 2011 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 11, 2011 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 10, 2011 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 10, 2011 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 10, 2011 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 8, 2010 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 8, 2010 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 8, 2010 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 17, 2010 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 17, 2010 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 17, 2010 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 23, 2010 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 23, 2010 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 23, 2010 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 26, 2010 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 26, 2010 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 26, 2010 | ALIE | ASSIGNED TO LIE | — |
| Jan 28, 2010 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 17, 2009 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 17, 2009 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 17, 2009 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 25, 2009 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 25, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 25, 2009 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 8, 2009 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 8, 2009 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 8, 2009 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 7, 2009 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 21, 2009 | MPMK | NOTICE OF PSEUDO MARK MAILED | — |
| Feb 20, 2009 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 20, 2009 | NWAP | NEW APPLICATION ENTERED | — |